CA2165830A1 - Salmeterol xinafoate with controlled particle size - Google Patents

Salmeterol xinafoate with controlled particle size

Info

Publication number
CA2165830A1
CA2165830A1 CA002165830A CA2165830A CA2165830A1 CA 2165830 A1 CA2165830 A1 CA 2165830A1 CA 002165830 A CA002165830 A CA 002165830A CA 2165830 A CA2165830 A CA 2165830A CA 2165830 A1 CA2165830 A1 CA 2165830A1
Authority
CA
Canada
Prior art keywords
particle size
salmeterol xinafoate
controlled particle
relates
products
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002165830A
Other languages
French (fr)
Other versions
CA2165830C (en
Inventor
Peter York
Mazen Hanna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Peter York
Mazen Hanna
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peter York, Mazen Hanna, Glaxo Group Limited filed Critical Peter York
Publication of CA2165830A1 publication Critical patent/CA2165830A1/en
Application granted granted Critical
Publication of CA2165830C publication Critical patent/CA2165830C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B01D11/0411—Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solvent and as anti-solvent for the solute, e.g. formation of particles from solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • C07C217/10—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids

Abstract

The invention relates to particulate products which may be prepared by methods and apparatus using supercritical fluids. More particularly the invention relates to pharmaceutical products, in particular easily handled and easily fluidised crystalline forms of salmeterol xinafoate, with controlled particle size and shape.
CA002165830A 1993-07-01 1994-06-30 Salmeterol xinafoate with controlled particle size Expired - Lifetime CA2165830C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939313650A GB9313650D0 (en) 1993-07-01 1993-07-01 Method and apparatus for the formation of particles
GB9313650.5 1993-07-01
PCT/GB1994/001425 WO1995001324A1 (en) 1993-07-01 1994-06-30 Salmeterol xinafoate with controlled particle size

Publications (2)

Publication Number Publication Date
CA2165830A1 true CA2165830A1 (en) 1995-01-12
CA2165830C CA2165830C (en) 2005-04-26

Family

ID=10738146

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002165830A Expired - Lifetime CA2165830C (en) 1993-07-01 1994-06-30 Salmeterol xinafoate with controlled particle size

Country Status (20)

Country Link
US (1) US5795594A (en)
EP (1) EP0706507B1 (en)
JP (1) JP3839042B2 (en)
CN (1) CN1062854C (en)
AT (1) ATE184870T1 (en)
AU (1) AU684795B2 (en)
BR (1) BR9406995A (en)
CA (1) CA2165830C (en)
DE (1) DE69420844T2 (en)
DK (1) DK0706507T3 (en)
ES (1) ES2138085T3 (en)
FI (1) FI956343A (en)
GB (1) GB9313650D0 (en)
GR (1) GR3032065T3 (en)
HK (1) HK1004216A1 (en)
HU (1) HUT73733A (en)
NO (1) NO304940B1 (en)
NZ (1) NZ267696A (en)
RU (1) RU2136655C1 (en)
WO (1) WO1995001324A1 (en)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0855906B1 (en) * 1995-10-17 2008-02-20 Jagotec AG Insoluble drug delivery
US5833891A (en) * 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5874029A (en) * 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US20020052310A1 (en) * 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
GB9622173D0 (en) 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
GB9806462D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Improved compositions for inhalation
GB9808802D0 (en) * 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
GB9810559D0 (en) * 1998-05-15 1998-07-15 Bradford Particle Design Ltd Method and apparatus for particle formation
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
SE9804001D0 (en) * 1998-11-23 1998-11-23 Astra Ab New process
EP1185248B1 (en) * 1999-06-09 2012-05-02 Robert E. Sievers Supercritical fluid-assisted nebulization and bubble drying
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
GB9915975D0 (en) * 1999-07-07 1999-09-08 Bradford Particle Design Ltd Method for the formation of particles
WO2001013891A2 (en) * 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US20010036481A1 (en) * 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
FR2798290B1 (en) * 1999-09-11 2003-09-12 Glaxo Group Ltd PHARMACEUTICAL FORMULATION OF FLUTICASONE PROPIONATE
FR2803538B1 (en) * 1999-12-15 2002-06-07 Separex Sa METHOD AND DEVICE FOR CAPTURING FINE PARTICLES BY PERCOLATION IN A BED OF GRANULES
US6761909B1 (en) 1999-12-21 2004-07-13 Rxkinetix, Inc. Particulate insulin-containing products and method of manufacture
AU2729101A (en) 1999-12-21 2001-07-03 Rxkinetix, Inc. Particulate drug-containing products and method of manufacture
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
US8551526B2 (en) * 2000-11-03 2013-10-08 Board Of Regents, The University Of Texas System Preparation of drug particles using evaporation precipitation into aqueous solutions
US6756062B2 (en) 2000-11-03 2004-06-29 Board Of Regents University Of Texas System Preparation of drug particles using evaporation precipitation into aqueous solutions
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
AU2002230993B2 (en) * 2000-12-29 2006-02-02 Alkermes, Inc. Particles for inhalation having sustained release properties
US20020141946A1 (en) * 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
BR0207570B1 (en) * 2001-02-26 2013-02-05 apparatus for forming micronized and submicronised particles of a substance, nozzle, and process performed using the apparatus.
EP1414633A4 (en) * 2001-07-10 2005-01-26 Univ Technology Corp Devices and methods for the production of particles
GB0117403D0 (en) * 2001-07-17 2001-09-05 Pharmacia & Upjohn Spa Solvent-free crystalline anthracycline derivatives
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
GB0117696D0 (en) * 2001-07-20 2001-09-12 Bradford Particle Design Plc Particle information
NZ532759A (en) * 2001-10-10 2005-10-28 Boehringer Ingelheim Pharma Powder processing with pressurized gaseous fluids
WO2003043603A1 (en) * 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Particulate compositions for improving solubility of poorly soluble agents
CA2465675C (en) * 2001-11-20 2008-06-10 Advanced Inhalation Research, Inc. Improved particulate compositions for pulmonary delivery
ES2364636T3 (en) 2001-12-19 2011-09-08 Novartis Ag PULMONARY ADMINISTRATION OF AMINOGLUCOSIDS.
US20050163725A1 (en) * 2002-03-20 2005-07-28 Blizzard Charles D. Method for administration of growth hormone via pulmonary delivery
US7008644B2 (en) * 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
JP2005521695A (en) * 2002-03-20 2005-07-21 アドバンスト インハレーション リサーチ，インコーポレイテッド Method of administering growth hormone by pulmonary delivery
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
WO2003090715A2 (en) * 2002-04-25 2003-11-06 Nektar Therapeutics Uk Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
US20040202681A1 (en) * 2002-12-19 2004-10-14 Baxter International, Inc. Process for preparing pharmaceutical formulations using supercritical fluids
DE10351663A1 (en) * 2002-12-20 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Stable, accurately dosable inhalable powder medicament for treating asthma or chronic obstructive pulmonary disease, containing tiotropium, specific form of salmeterol xinafoate and auxiliary
US20040152720A1 (en) * 2002-12-20 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powdered medicaments containing a tiotropium salt and salmeterol xinafoate
MXPA05007154A (en) * 2002-12-30 2005-09-21 Nektar Therapeutics Prefilming atomizer.
US6915966B2 (en) * 2003-01-29 2005-07-12 Specialty Minerals (Michigan) Inc. Apparatus for the gunning of a refractory material and nozzles for same
MY147403A (en) * 2003-04-29 2012-11-30 Kowa Co Composition containing medicine extremely slightly solube in water and method for preparation thereof
AU2004237131B2 (en) 2003-05-08 2009-09-10 Nektar Therapeutics Particulate materials
JP4206317B2 (en) * 2003-09-10 2009-01-07 花王株式会社 Method for producing organic plate-like particles
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
EP1949891A1 (en) 2004-10-12 2008-07-30 Generics (UK) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
US9808423B2 (en) * 2004-10-12 2017-11-07 Generics [Uk] Limited Preparation of suspension aerosol formulations
US7854397B2 (en) * 2005-01-21 2010-12-21 Specialty Minerals (Michigan) Inc. Long throw shotcrete nozzle
WO2007009164A1 (en) 2005-07-15 2007-01-25 Eiffel Technologies Limited Method of particle formation
US20070021605A1 (en) * 2005-07-20 2007-01-25 Rolf Keltjens Process and composition for making olanzapine form i
WO2007020080A1 (en) * 2005-08-17 2007-02-22 Synthon B.V. A process for making olanzapine form i
WO2007067566A2 (en) * 2005-12-07 2007-06-14 Wyeth Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
CL2007002807A1 (en) * 2006-09-29 2008-04-11 Synthon Bv PHARMACEUTICAL COMPOSITION IN SOLID STATE THAT INCLUDES OLANZAPINE OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME AND LACTOSE ANHYDRA; ORAL PHARMACEUTICAL TABLET; PROCEDURE FOR PREPARATION OF SUCH TABLET, USEFUL IN THE TREATMENT OF SKI
CN1973812B (en) * 2006-11-03 2010-12-08 谭登平 Method of powdering supercritical CO2 solid extract
CN104188907A (en) 2007-02-11 2014-12-10 Map药物公司 Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
EP2127641A1 (en) * 2008-05-26 2009-12-02 Inke, S.A. Micronisable form of salmeterol xinafoate
WO2012032546A2 (en) 2010-09-08 2012-03-15 Cadila Healthcare Limited Process for the preparation of salmeterol and its intermediates
MX350838B (en) 2011-02-11 2017-09-18 Grain Proc Corporation * Salt composition.
US9908062B2 (en) 2012-11-20 2018-03-06 Andrew Paul Joseph Extraction apparatus and method
US9132363B2 (en) 2012-11-20 2015-09-15 Apeks Llc Extraction system
JP2021141003A (en) * 2020-03-07 2021-09-16 エムテックスマート株式会社 Manufacturing method of secondary battery or secondary battery
WO2021219230A1 (en) 2020-04-30 2021-11-04 Paolo Fiorina Antiviral treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3744329A1 (en) * 1987-12-28 1989-07-06 Schwarz Pharma Gmbh METHOD FOR THE PRODUCTION OF AT LEAST ONE ACTIVE AGENT AND A TRAITER COMPRISING PREPARATION
AU663906B2 (en) * 1991-12-12 1995-10-26 Glaxo Group Limited Medicaments
US5509404A (en) * 1994-07-11 1996-04-23 Aradigm Corporation Intrapulmonary drug delivery within therapeutically relevant inspiratory flow/volume values

Also Published As

Publication number Publication date
EP0706507B1 (en) 1999-09-22
CN1062854C (en) 2001-03-07
NO955355D0 (en) 1995-12-29
ATE184870T1 (en) 1999-10-15
DE69420844T2 (en) 2000-03-16
AU7007094A (en) 1995-01-24
FI956343A (en) 1996-02-15
DK0706507T3 (en) 2000-04-10
NZ267696A (en) 1997-11-24
ES2138085T3 (en) 2000-01-01
FI956343A0 (en) 1995-12-29
HU9503772D0 (en) 1996-02-28
JP3839042B2 (en) 2006-11-01
WO1995001324A1 (en) 1995-01-12
EP0706507A1 (en) 1996-04-17
GR3032065T3 (en) 2000-03-31
NO955355L (en) 1996-02-29
DE69420844D1 (en) 1999-10-28
CA2165830C (en) 2005-04-26
US5795594A (en) 1998-08-18
HUT73733A (en) 1996-09-30
BR9406995A (en) 1996-09-10
GB9313650D0 (en) 1993-08-18
HK1004216A1 (en) 1998-11-20
AU684795B2 (en) 1998-01-08
RU2136655C1 (en) 1999-09-10
CN1129932A (en) 1996-08-28
JPH08512047A (en) 1996-12-17
NO304940B1 (en) 1999-03-08

Similar Documents

Publication Publication Date Title
CA2165830A1 (en) Salmeterol xinafoate with controlled particle size
CA2192680A1 (en) Flash flow formed solloid delivery systems
ZA913164B (en) Apparatus for orienting spherical products having at least one substantially flattened surface,such as tomatoes and the like
ZA976967B (en) Device and process for separating magnetic materials from pharmaceutical preparations, their starting or intermediate products, as well as agents that are produced with the of said device.
AU689345B2 (en) Iminooxymethylene anilides, process and intermediate products for preparing the same and pesticides containing the same
HUT67142A (en) Spirostanil glycosidal cristalline monohydrate, pharmaceutical compositions containing the same and process for their production
AU1320495A (en) Use of 2-mercapto-imidazole derivatives substituted in position 4 (or 5) as antioxidizing agents, method of preparation and applications in the pharmaceutical, cosmetic or food industries
AU3970793A (en) Methods of manufacturing high dosage glutathione, the tablets and capsules produced thereby
HUT67599A (en) Process for producing dry- processed particles, the produced dry-processed particles, and pharmaceutical compositions containing them
NO308705B1 (en) Particulate material comprising titanium dioxide, process for its preparation and dispersion comprising the material
ITPR930006A0 (en) PROCEDURE FOR THE FORMATION OF BACKED FOOD PRODUCTS, IN PARTICULAR MORTADELLE, AND PRODUCT OBTAINED WITH SAID PROCEDURE.
AU1865692A (en) Method and apparatus for inducing controlled stressed behavior in animals, such as enhanced eating, drinking, mating, maternal or the like behavior
HUT71793A (en) 2,4-diamino-3-hydroxy-carboxylic acid derivatives, pharmaceutical compns. contg. them and process for producing the said compds.
AU3010589A (en) Trisubstituted amines, processes for the preparation thereof and pharmaceutical compositions containing them
AU5301094A (en) Process for the recovery of valuable substances, in particular carotinoids from algae and installations suitable therefor
HUT69285A (en) Ethanolamine derivatives, pharmaceutical compns. contg. them and process to prepare the sald compds.
AU1482292A (en) Pharmaceutical composition and process for the preparation thereof
IL104745A0 (en) 90k tumor-associated antigen,method for the preparation thereof and pharmaceutical compositions containing the same
AU3081592A (en) Powdered or granulated protein product, process for the preparation thereof, and foodstuff containing the protein product
AU5695594A (en) Thio- and oxo-azasteroids, processes for the preparation thereof, use thereof as antiandrogens and pharmaceutical compositions containing them
AU690368B2 (en) 2-(4-biphenyl-oxymethylene)anilides, process and intermediate products for preparing the same and their use as pesticides
ZA924969B (en) Pyrethrinoid esters of 2,3-dihydro-4-methyl-2-oxo-3-(2-propynyl)-thiazol-5-yl methyl alcohol, their preparation process and their use as pesticides.
AU3952493A (en) Process for forming packaged solidificable food products, in particular hand-held ice-creams and container for implementing the process
CA2155219A1 (en) Method and device for the manufacture of products
ZA925373B (en) Anti-glaucomatous pharmaceutical compositions and the process for obtaining them.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20140630